Comprehensive analysis of kinase inhibitor selectivity

Nature Biotechnology

Volumn 29, Issue 11, 2011, Pages 1046-1051

  Davis, Mindy I ^a,b   Hunt, Jeremy P ^a,b,c   Herrgard, Sanna ^a   Ciceri, Pietro ^a,b,c   Wodicka, Lisa M ^a,b,c   Pallares, Gabriel ^a,b,c   Hocker, Michael ^a   Treiber, Daniel K ^a,b,c   Zarrinkar, Patrick P ^a,b,d  

^a Ambit Biosciences   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c DiscoveRx Corporation   (United States)

^d Blueprint Medicines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC RESEARCH; CATALYTIC PROTEINS; CELLULAR SIGNALING; COMPREHENSIVE ANALYSIS; DATA SETS; DRUG DEVELOPMENT; GENOMICS; INTERACTION PATTERN; KINASE INHIBITORS; SELECTIVE INHIBITORS; STRUCTURAL BASIS; TYPE II;

ENZYMES;

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; AFATINIB; AST 487; BARASERTIB; BRIVANIB; CRIZOTINIB; DOVITINIB; EXEL 2880; FORETINIB; FOSTAMATINIB; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; RUXOLITINIB; SELUMETINIB; STAUROSPORINE; SUNITINIB; TASOCITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG SELECTIVITY; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

CATALYSIS; DRUG DESIGN; ENZYME STABILITY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 80755125575     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1990     Document Type: Article

References (30)

1. Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204 (2003). (Pubitemid 36458094)
2. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007). (Pubitemid 47517638)
3. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005). (Pubitemid 41094421)
4. Melnick, J.S. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl. Acad. Sci. USA 103, 3153-3158 (2006). (Pubitemid 43346440)
5. Patricelli, M.P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350-358 (2007). (Pubitemid 46105428)
6. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523-20528 (2007).
7. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
8. Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898-7914 (2008).
9. Posy, S.L. et al. Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem. 54, 54-66 (2011).
10. Metz, J.T. et al. Navigating the kinome. Nat. Chem. Biol. 7, 200-202 (2011).
11. Liu, Y. & Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364 (2006). (Pubitemid 43936934)
12. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002). (Pubitemid 35425239)
13. Zarrinkar, P.P. et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114, 2984-2992 (2009).
14. Ohren, J.F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197 (2004).
15. Buchanan, S.G. et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther. 8, 3181-3190 (2009).
16. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004). (Pubitemid 39297926)
17. Simard, J.R. et al. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. J. Am. Chem. Soc. 132, 4152-4160 (2010).
18. Wodicka, L.M. et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol. 17, 1241-1249 (2010).
19. Carlomagno, F. et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23, 6056-6063 (2004). (Pubitemid 39178858)
20. Goldstein, D.M., Gray, N.S. & Zarrinkar, P.P. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7, 391-397 (2008). (Pubitemid 351619111)
21. Kwiatkowski, N. et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat. Chem. Biol. 6, 359-368 (2010).
22. Deng, X. et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7, 203-205 (2011).
23. Hasinoff, B.B. & Patel, D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol. Appl. Pharmacol. 249, 132-139 (2010).
24. Huang, D., Zhou, T., Lafleur, K., Nevado, C. & Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics 26, 198-204 (2010).
25. Olaharski, A.J. et al. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLOS Comput. Biol. 5, e1000446 (2009).
26. Yang, X. et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43, 376-384 (2010).
27. Remsing Rix, L.L. et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23, 477-485 (2009).
28. Knight, Z.A., Lin, H. & Shokat, K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010).
29. Miduturu, C.V. et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18, 868-879 (2011).
30. Cortes, J. et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase I clinical trial. Blood (ASH Annual Meeting Abstracts) 114, Abstract 636 (2009).